Examining Melanoma Risk in Patients Treated With Biologics for Common Inflammatory Diseases

JAMA Dermatology

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, MAY 20, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2020.1300?guestAccessKey=eb3d5444-37f1-4cd5-8a1d-eede84da416b&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=052020

 

What The Study Did: This study combined the results of seven studies and compared the risk of melanoma among 34,000 patients treated with biologics and 135,000 patients treated with conventional systemic therapy for rheumatoid arthritis, psoriasis or inflammatory bowel disease.

Authors: Shamarke Esse, M.Res., of the University of Manchester in the United Kingdom, is the corresponding author.

 

(doi:10.1001/jamadermatol.2020.1300)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.